Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.10.0.1
Business (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 14, 2017
USD ($)
Aug. 31, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
application
product
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Subsequent Event [Line Items]              
License and other revenue     $ 4,074,786 $ 25,037,592 $ 13,342,699 $ 25,579,597  
Number of investigational new drug applications expected in next calendar year | application         2    
Number of marketed medical devices | product         1    
Escrowed cash receivable $ 3,750,000   0   $ 0   $ 3,752,390
Escrow period 12 months            
Potential future regulatory milestone payment   $ 20,000,000          
Net (loss) income     (24,603,575) 18,720,610 (34,493,895) 14,961,458  
Cash flows from operations         (1,152,446) 15,127,845  
Accumulated deficit     (92,659,155)   (92,659,155)   (58,165,260)
Cash and cash equivalents     6,838,353 23,955,397 $ 6,838,353 23,955,397 $ 2,472,187
Neurological Clinical And Preclinical Stage Compounds              
Subsequent Event [Line Items]              
Number of products in development | product         3    
Preclinical Pediatric Orphan Rare Disease Compound              
Subsequent Event [Line Items]              
Number of products in development | product         1    
License and other revenue              
Subsequent Event [Line Items]              
License and other revenue $ 25,000,000   $ 0 $ 25,000,000 $ 0 $ 25,000,000